{"organizations": [], "uuid": "ca1999b0b4392949527e1b05f31539d3b8fa1f38", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/16/globe-newswire-bellicum-pharmaceuticals-announces-proposed-public-offering-of-common-stock.html", "country": "US", "domain_rank": 767, "title": "Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T00:42:00.000+03:00", "replies_count": 0, "uuid": "ca1999b0b4392949527e1b05f31539d3b8fa1f38"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/16/globe-newswire-bellicum-pharmaceuticals-announces-proposed-public-offering-of-common-stock.html", "ord_in_thread": 0, "title": "Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock", "locations": [], "entities": {"persons": [{"name": "bellicum", "sentiment": "none"}], "locations": [{"name": "houston", "sentiment": "none"}], "organizations": [{"name": "bellicum pharmaceuticals announces proposed public offering of common stock", "sentiment": "negative"}, {"name": "bellicum pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "citigroup", "sentiment": "none"}, {"name": "jefferies llc", "sentiment": "none"}, {"name": "securities and exchange commi", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "HOUSTON, April 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Bellicum. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.\nCitigroup and Jefferies LLC are acting as lead book-running managers for the offering. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.\nThe securities described above are being offered by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 12, 2017. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Bellicum Pharmaceuticals, Inc.\nBellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including CAR-T, TCR, and hematopoietic stem cell transplantation (HSCT) therapies. Bellicum is based in Houston, Texas.\nForward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “expected,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the completion and size of its public offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering, as well as those discussed in greater detail in Bellicum’s filings with the SEC, including without limitation in its Form 10-K for the year ended December 31, 2017. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.\nBellicum Pharmaceuticals\nInvestors: Bellicum Pharmaceuticals, Inc., Alan Musso, CFO 832-384-1116 amusso@bellicum.com Media: BMC Communications, Brad Miles, 646-513-3125 bmiles@bmccommunications.com\nSource:Bellicum Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/367763ec-20f1-4adf-8ddb-a01e966e31e3"], "published": "2018-04-17T00:42:00.000+03:00", "crawled": "2018-04-17T03:58:16.016+03:00", "highlightTitle": ""}